Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.R-Tech Ueno has initiated a Phase I clinical study of RK-023, a new compound that is being developed for the treatment of hypotrichosis of the eyelashes.
Subscribe to our email newsletter
The placebo-controlled, double-blind study evaluates the safety, tolerability, and pharmacokinetics of RK-023 in healthy adult male and female volunteers, who will apply the study drug to the eyelid margin for five consecutive days.
The study is being conducted in Japan and the UK, aiming at the global development of the drug
As there is a possibility of the drug solution entering into eyes when the study drug is applied, the company plans to conduct another Phase I clinical study in Japan to assess the safety and pharmacokinetics of a single instillation of RK-023 into the eyes of healthy adult male volunteers.